Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

Recruiting now · Phase 2

Conditions studied: Multiple Myeloma, Relapsed/Refractory

In brief

To evaluate the safety and tolerability of chimeric antigen receptor gene-modified T cells targeting BCMA for the treatment of relapsed/refractory multiple myeloma

Key facts

Study ID

NCT06581640

Run by

The First Affiliated Hospital of Xiamen University

People needed

5

Starts

2024-09-24

Expected to finish

2028-12-31

Last updated by the study team

2024-09-25

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-80 years, no gender restrictions;
• Diagnosed with refractory/relapsed multiple myeloma through physical examination, pathological examination, laboratory tests, and imaging studies;
• Flow cytometry or histology confirms positive BCMA expression in myeloma cells;
• As judged by the investigator, the expected survival time is >3 months;
• ECOG performance status score ≤2, KPS >60%;
• The patient has good liver, kidney, heart, and lung function: ALT and AST ≤2.5×ULN, those with liver involvement can be relaxed to ≤5×ULN; serum total bilirubin <34 μmol/L; creatinine clearance rate >30 mL/min; heart ejection fraction (EF) ≥40%, no pericardial effusion and significant arrhythmia; indoor SpO2 ≥92%;
• Peripheral blood lymphocyte absolute count ALC ≥0.5 ×10\^9/L, PLT >30×10\^9/L, Hb >80 g/L and has a single collection venous access, and there are no other contraindications for hematopoietic cell separation;
• Those with fertility must agree to use highly effective contraceptive methods;
• The subject or their legal guardian can understand and is willing to sign a written informed consent form voluntarily.

You may not qualify if…

• Pregnant or nursing women, as well as women planning to become pregnant within the next six months;
• Positive virology tests for hepatitis B, hepatitis C, HIV, syphilis, or cytomegalovirus;
• History of other tumors (except for those with skin or cervical in situ cancers that have been cured by radical treatment and show no evidence of disease activity);
• Previously received treatment targeting BCMA;
• Underwent autologous hematopoietic stem cell transplantation within the last 6 weeks;
• Presence of uncontrolled active bacterial or fungal infection;
• Allergic to research-related drugs or cell components;
• Presence of active autoimmune diseases;
• Currently have unstable or active ulcers or gastrointestinal bleeding;
• Unable to cooperate with treatment and efficacy evaluation due to mental or psychological disorders;
• Received other experimental drug treatments within the last 3 months;
• The researcher believes that for other reasons, the individual is not suitable for the clinical trial.

Where it is running

• The First Affiliated Hospital of Xiamen University — Xiamen, Fujian, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.